Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Central and peripheral α-synuclein in Parkinson disease detected by seed amplification assay.
Chahine LM, Beach TG, Adler CH, Hepker M, Kanthasamy A, Appel S, Pritzkow S, Pinho M, Mosovsky S, Serrano GE, Coffey C, Brumm MC, Oliveira LMA, Eberling J, Mollenhauer B; Systemic Synuclein Sampling Study. Chahine LM, et al. Among authors: eberling j. Ann Clin Transl Neurol. 2023 May;10(5):696-705. doi: 10.1002/acn3.51753. Epub 2023 Mar 27. Ann Clin Transl Neurol. 2023. PMID: 36972727 Free PMC article.
Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.
Oertel WH, Müller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT. Oertel WH, et al. Among authors: eberling j. NEJM Evid. 2023 Sep;2(9):EVIDoa2200311. doi: 10.1056/EVIDoa2200311. Epub 2023 Aug 22. NEJM Evid. 2023. PMID: 38320207 Clinical Trial.
Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial.
Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, Videnovic A, Kenney CJ; Parkinson Study Group SYNAPSE Investigators. Fernandez HH, et al. Among authors: eberling j. Parkinsonism Relat Disord. 2023 Sep;114:105511. doi: 10.1016/j.parkreldis.2023.105511. Epub 2023 Jul 13. Parkinsonism Relat Disord. 2023. PMID: 37532622 Clinical Trial.
Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence.
Signaevsky M, Marami B, Prastawa M, Tabish N, Iida MA, Zhang XF, Sawyer M, Duran I, Koenigsberg DG, Bryce CH, Chahine LM, Mollenhauer B, Mosovsky S, Riley L, Dave KD, Eberling J, Coffey CS, Adler CH, Serrano GE, White CL 3rd, Koll J, Fernandez G, Zeineh J, Cordon-Cardo C, Beach TG, Crary JF. Signaevsky M, et al. Among authors: eberling j. Acta Neuropathol Commun. 2022 Feb 14;10(1):21. doi: 10.1186/s40478-022-01318-7. Acta Neuropathol Commun. 2022. PMID: 35164870 Free PMC article.
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
Barker RA, Björklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. Barker RA, et al. Among authors: eberling j. J Parkinsons Dis. 2020;10(3):875-891. doi: 10.3233/JPD-202004. J Parkinsons Dis. 2020. PMID: 32508331 Free PMC article. Review.
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease.
Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M; Parkinson’s Progression Markers Initiative. Weintraub D, et al. Among authors: eberling j. Ann Clin Transl Neurol. 2020 Apr;7(4):449-461. doi: 10.1002/acn3.51022. Epub 2020 Apr 13. Ann Clin Transl Neurol. 2020. PMID: 32285645 Free PMC article.
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group. Merchant KM, et al. Among authors: eberling j. J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471. J Parkinsons Dis. 2019. PMID: 30400107 Free PMC article.
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative. Mollenhauer B, et al. Neurology. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13. Neurology. 2017. PMID: 29030452 Free PMC article.
78 results